These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 31236690)

  • 21. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy.
    McLeod CJ; Shen WK; Rea RF; Friedman PA; Hayes DL; Wokhlu A; Webster TL; Wiste HJ; Hodge DO; Bradley DJ; Hammill SC; Packer DL; Cha YM
    Heart Rhythm; 2011 Mar; 8(3):377-82. PubMed ID: 21070886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocardial Scar But Not Ischemia Is Associated With Defibrillator Shocks and Sudden Cardiac Death in Stable Patients With Reduced Left Ventricular Ejection Fraction.
    Gupta A; Harrington M; Albert CM; Bajaj NS; Hainer J; Morgan V; Bibbo CF; Bravo PE; Osborne MT; Dorbala S; Blankstein R; Taqueti VR; Bhatt DL; Stevenson WG; Di Carli MF
    JACC Clin Electrophysiol; 2018 Sep; 4(9):1200-1210. PubMed ID: 30236394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left atrial booster pump function is an independent predictor of subsequent life-threatening ventricular arrhythmias in non-ischaemic cardiomyopathy.
    Negishi K; Negishi T; Zardkoohi O; Ching EA; Basu N; Wilkoff BL; Popović ZB; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2016 Oct; 17(10):1153-60. PubMed ID: 26710819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.
    Grimm W; Timmesfeld N; Efimova E
    Europace; 2013 Nov; 15(11):1594-600. PubMed ID: 23639855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of remote monitoring on long-term cardiovascular outcomes after cardioverter-defibrillator implantation.
    Portugal G; Cunha P; Valente B; Feliciano J; Lousinha A; Alves S; Braz M; Pimenta R; Delgado AS; Oliveira M; Ferreira RC
    Int J Cardiol; 2016 Nov; 222():764-768. PubMed ID: 27521554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
    Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
    JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
    Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
    Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preserved heart rate variability identifies low-risk patients with nonischemic dilated cardiomyopathy: results from the DEFINITE trial.
    Rashba EJ; Estes NA; Wang P; Schaechter A; Howard A; Zareba W; Couderc JP; Perkiomaki J; Levine J; Kadish A
    Heart Rhythm; 2006 Mar; 3(3):281-6. PubMed ID: 16500299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chagas disease is associated with a worse prognosis at 1-year follow-up after implantable cardioverter-defibrillator for secondary prevention in heart failure patients.
    Vieira de Melo RM; de Azevedo DFC; Lira YM; Cardoso de Oliveira NF; Passos LCS
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2448-2452. PubMed ID: 31502385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
    Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
    Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.
    Evonich RF; Maheshwari A; Gardiner JC; Khasnis A; Kantipudi S; Ip JH; Grimes D; Hayter G; Thakur RK
    J Interv Card Electrophysiol; 2004 Aug; 11(1):59-65. PubMed ID: 15273456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
    Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV
    Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.